Q4 and Year End Earnings Release and Business Highlights
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the œCompany or œHCW Biologics) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
MIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (œHCW Biologics or the œCompany) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases